We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Says Way Cleared for Lemtrada Resubmission
Genzyme will resubmit its application for an expanded indication in relapsing multiple sclerosis for Lemtrada during the second quarter, following “constructive” talks with the FDA, the company said Monday.